EWTX

Edgewise Therapeutics Inc. (EWTX) | Rumor.io

Edgewise Therapeutics

EWTX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,470

Bullish sentiment (50-day avg)78%

Price to earnings ratio-24.4

Market capitalization4.3B

Earnings per share-1.85

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-167.8M

Social

What share of all stock conversation is about EWTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Jul 2

Edgewise Therapeutics, Inc. (EWTX) insider Russell Alan J sold 200,000 shares for $7.88M, reducing their position by 68%.
The sale represents 0.19% of shares outstanding and was made at an average price of $39.41 per share.
Russell Alan J, Chief Scientific Officer, disposed of 89.07% of their shares, selling a total of $7.9M worth of EWTX.

Generated by AI

Sentiment

Of the messages about EWTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	52.17% -35.13	96.67% +4.25
Bearish	—	—	47.83% +35.13	3.33% -4.25

Bullish· Dec 24

$EWTX has a strong cash runway exceeding $1/2 billion, supporting the company's cash needs through the launch of Sevasemten for Becker's muscular dystrophy.
Edgewise Therapeutics' stock has confirmed a major technical breakout, surging +21.89% to $26.51, with high volume of 1.83M shares confirming institutional momentum.
$EWTX is heading for a strong close, driven by stellar Phase 2 HCM data, with 70% of patients on 100mg+ doses, and a Phase 3 launch expected in 2026 Q4, outshining CMIs and earning an RBC Buy rating with a $49 target.

Bearish· Sep 19

The largest shareholders of Edgewise Therapeutics, Inc. (EWTX) are also significant shareholders of another company ($ACET), which may indicate a conflict of interest or lack of focus on EWTX.
EWTX is experiencing a "dead cat bounce" and may be due for a significant decline in price, making it a good candidate for shorting.
EWTX has only announced phase 1 news, which is not enough to sustain its current price level, and it may plummet back down as a result.

Generated by AI

Topics

Of the messages about EWTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	29.46%	66.45%
Technical Analysis	—	—	70.54%	16.17%
Controversies	—	—	0%	3.88%
Analysts	—	—	0%	13.42%
Earnings	—	—	0%	0%
Macro	—	—	0%	0.08%

Jun 1

Edgewise Therapeutics ($EWTX) has agreed to sell its muscular dystrophy drug business to Servier for up to $2.65 billion.
The transaction includes $1.55 billion in upfront cash and up to $1.1 billion in milestone payments.
Edgewise will focus on its cardiovascular pipeline, including the EDG-7500 program for hypertrophic cardiomyopathy.

Generated by AI

Community

Of the messages about EWTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	60%	86.55%	53.04%
Newcomers	0%	40%	13.45%	46.96%

Jun 1

Edgewise Therapeutics has agreed to sell its muscular dystrophy drug business to Servier for up to $2.65 billion, with $1.55 billion paid upfront.
The transaction will allow Edgewise to focus on its cardiovascular pipeline and has the potential to fully fund the development of its EDG-7500 treatment through potential approval.
The deal is seen as a transformative agreement for Edgewise, securing its funding and paving the way for future developments, with the company's stock price increasing on the news.

Generated by AI

News

Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says

4d agofinance.yahoo.com

Edgewise's EDG-7500 Mechanism Lends Confidence, RBC Says

Edgewise Therapeutics' (EWTX) EDG-7500 mechanism reveal accounts for strong clinical showing, lendin

6d agoYahoo Finance

Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 - Slideshow (NASDAQ:EWTX) 2026-09-22

7d agoSeeking Alpha

Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy - Slideshow (NASDAQ:EWTX) 2026-06-17

2026-06-17. The following slide deck was published by Edgewise Therapeutics, Inc.

7d agoSeeking Alpha

Edgewise unveils mechanism of action for heart drug EDG-7500

8d agoInvesting.com

Edgewise Therapeutics options flow shows lopsided call activity

11d agoInvesting.com

Also Discussed

Investors talking about EWTX also mention

#	Name	Attention
1	Mineralys Therapeutics, Inc.MLYS	0%+0
2	IDEAYA Biosciences Inc.IDYA	0%-0.01
3	Abivax SAABVX	0.01%-0.01
4	Cytokinetics, IncorporatedCYTK	0.01%+0
5	Revolution Medicines, Inc.RVMD	0.01%-0.01
6	SWTX - SpringWorks Therapeutics, Inc.	——
7	Spyre Therapeutics, Inc.SYRE	0%new
8	Crinetics Pharmaceuticals IncCRNX	0%new
9	Structure Therapeutics Inc. American Depositary SharesGPCR	0%new
10	Janux Therapeutics, Inc.JANX	0%0

Edgewise Therapeutics Inc.

Healthcare
Biotechnology

Edgewise Therapeutics Inc. is a biopharmaceutical company focused on developing therapies for severe muscle and cardiac disorders. The company’s current portfolio centers on precision medicine programs designed to address rare neuromuscular diseases and inherited heart conditions, with a platform built around small-molecule approaches that target key muscle proteins and pathways. Its work spans muscular dystrophy and hypertrophic cardiomyopathy research, as well as other disorders where abnormal muscle function plays a central role. Edgewise Therapeutics Inc. operates as a clinical-stage developer of medicines aimed at improving how muscle diseases are treated in specialized medical settings, supporting both neuromuscular and cardiovascular care.

Website

Location

1715 38th Street

Boulder, CO, 80301

United States

Social

What share of all stock conversation is about EWTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Jul 2

Edgewise Therapeutics, Inc. (EWTX) insider Russell Alan J sold 200,000 shares for $7.88M, reducing their position by 68%.
The sale represents 0.19% of shares outstanding and was made at an average price of $39.41 per share.
Russell Alan J, Chief Scientific Officer, disposed of 89.07% of their shares, selling a total of $7.9M worth of EWTX.

Generated by AI

Sentiment

Of the messages about EWTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	52.17% -35.13	96.67% +4.25
Bearish	—	—	47.83% +35.13	3.33% -4.25

Bullish· Dec 24

$EWTX has a strong cash runway exceeding $1/2 billion, supporting the company's cash needs through the launch of Sevasemten for Becker's muscular dystrophy.
Edgewise Therapeutics' stock has confirmed a major technical breakout, surging +21.89% to $26.51, with high volume of 1.83M shares confirming institutional momentum.
$EWTX is heading for a strong close, driven by stellar Phase 2 HCM data, with 70% of patients on 100mg+ doses, and a Phase 3 launch expected in 2026 Q4, outshining CMIs and earning an RBC Buy rating with a $49 target.

Bearish· Sep 19

The largest shareholders of Edgewise Therapeutics, Inc. (EWTX) are also significant shareholders of another company ($ACET), which may indicate a conflict of interest or lack of focus on EWTX.
EWTX is experiencing a "dead cat bounce" and may be due for a significant decline in price, making it a good candidate for shorting.
EWTX has only announced phase 1 news, which is not enough to sustain its current price level, and it may plummet back down as a result.

Generated by AI

Topics

Of the messages about EWTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	29.46%	66.45%
Technical Analysis	—	—	70.54%	16.17%
Controversies	—	—	0%	3.88%
Analysts	—	—	0%	13.42%
Earnings	—	—	0%	0%
Macro	—	—	0%	0.08%

Jun 1

Edgewise Therapeutics ($EWTX) has agreed to sell its muscular dystrophy drug business to Servier for up to $2.65 billion.
The transaction includes $1.55 billion in upfront cash and up to $1.1 billion in milestone payments.
Edgewise will focus on its cardiovascular pipeline, including the EDG-7500 program for hypertrophic cardiomyopathy.

Generated by AI

Community

Of the messages about EWTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	60%	86.55%	53.04%
Newcomers	0%	40%	13.45%	46.96%

Jun 1

Edgewise Therapeutics has agreed to sell its muscular dystrophy drug business to Servier for up to $2.65 billion, with $1.55 billion paid upfront.
The transaction will allow Edgewise to focus on its cardiovascular pipeline and has the potential to fully fund the development of its EDG-7500 treatment through potential approval.
The deal is seen as a transformative agreement for Edgewise, securing its funding and paving the way for future developments, with the company's stock price increasing on the news.

Generated by AI

Edgewise Therapeutics

Social

Jul 2

Bullish· Dec 24

Bearish· Sep 19

Jun 1

Jun 1

Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says

Edgewise's EDG-7500 Mechanism Lends Confidence, RBC Says

Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 - Slideshow (NASDAQ:EWTX) 2026-09-22

Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy - Slideshow (NASDAQ:EWTX) 2026-06-17

Edgewise unveils mechanism of action for heart drug EDG-7500

Edgewise Therapeutics options flow shows lopsided call activity

Also Discussed

Edgewise Therapeutics Inc.

Company Information

Location

Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says

Edgewise's EDG-7500 Mechanism Lends Confidence, RBC Says

Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 - Slideshow (NASDAQ:EWTX) 2026-09-22

Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy - Slideshow (NASDAQ:EWTX) 2026-06-17

Edgewise unveils mechanism of action for heart drug EDG-7500

Edgewise Therapeutics options flow shows lopsided call activity

Also Discussed

Social

Jul 2

Bullish· Dec 24

Bearish· Sep 19

Jun 1

Jun 1